All In Biotech

Drug Trial Radar · NCT05579860

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

A Single-Dose, Randomized, Open-Label, Two-Period Crossover, Bioequivalence Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Oct 5, 2022

Primary completion

May 22, 2023

Study completion May 22, 2023

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the bioequivalence of olezarsen between 2 subcutaneous (SC) formulations \[(autoinjector (AI) and vial\] at 2 dose levels in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • OlezarsenDrug

    Olezarsen will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve (AUC) of olezarsen from time 0 to 336 hours (AUC0-336h)Time frame: Up to Day 8 of each of Treatment Periods 1 and 2
  2. Maximum plasma concentration of olezarsen (Cmax)Time frame: Up to Day 91 of Treatment Period 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace Clinical Pharmacology Unit

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.